UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Clinical cancer research, 2017-06, Vol.23 (12), p.3012-3024

2017

Volltextzugriff (PDF)

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Journal of clinical oncology, 2021-03, Vol.39 (7), p.713-722

2021

Volltextzugriff (PDF)

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Journal of clinical oncology, 2019-09, Vol.37 (25), p.2235-2245

2019

Volltextzugriff (PDF)

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.1723-1727

2017

Volltextzugriff (PDF)

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

The New England journal of medicine, 2009-09, Vol.361 (10), p.947-957

2009

Volltextzugriff (PDF)

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Clinical cancer research, 2017-08, Vol.23 (16), p.4929-4937

2017

Volltextzugriff (PDF)

Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1081-1088

2013

Volltextzugriff (PDF)

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status

PloS one, 2012-06, Vol.7 (6), p.e40109-e40109

2012

Volltextzugriff (PDF)

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

BMC cancer, 2016-02, Vol.16 (147), p.149-149, Article 149

2016

Volltextzugriff (PDF)

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Clinical cancer research, 2017-09, Vol.23 (18), p.5480-5488

2017

Volltextzugriff (PDF)

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.924-932

2019

Volltextzugriff (PDF)

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

The oncologist (Dayton, Ohio), 2012-07, Vol.17 (7), p.978-985

2012

Volltextzugriff (PDF)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Molecular oncology, 2023-08, Vol.17 (8), p.1581-1594

2023

Volltextzugriff (PDF)

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Investigational new drugs, 2021-04, Vol.39 (2), p.477-487

2021

Volltextzugriff (PDF)

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1415-1421

2018

Volltextzugriff (PDF)

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3316-3321

2011

Volltextzugriff (PDF)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

BMC medicine, 2022-05, Vol.20 (1), p.197-197, Article 197

2022

Volltextzugriff (PDF)

CT-Guided Percutaneous Cryoablation for Lung Metastasis of Colorectal Cancer: A Case Series

Technology in cancer research & treatment, 2023-01, Vol.22, p.15330338231201508-15330338231201508

2023

Volltextzugriff (PDF)

Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study

Genes chromosomes & cancer, 2022-04, Vol.61 (4), p.177-186

2022

Volltextzugriff (PDF)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Biomarker research, 2020-06, Vol.8 (1), p.22-22, Article 22

2020

Volltextzugriff (PDF)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Experimental hematology & oncology, 2021-11, Vol.10 (1), p.1-52, Article 52

2021

Volltextzugriff (PDF)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

BMC cancer, 2018-11, Vol.18 (1), p.1171-1171, Article 1171

2018

Volltextzugriff (PDF)

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

International journal of clinical oncology, 2020-02, Vol.25 (2), p.267-273

2020

Volltextzugriff (PDF)

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Cancer Immunology, Immunotherapy, 2022-06, Vol.71 (6), p.1393-1402

2022

Volltextzugriff (PDF)

1 – 25 von 693

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(568)
Mit Volltextzugriff
(623)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(415)
Life Sciences & Biomedicine
(345)
Humans
(233)
Male
(170)
Female
(158)
Oncology
(152)
Middle Aged
(138)
Aged
(109)
Adult
(99)
Lung Cancer
(79)
Lung Neoplasms - Genetics
(76)
Mutation
(68)
Lung Neoplasms - Drug Therapy
(64)
General & Internal Medicine
(61)
Medicine, General & Internal
(59)
Carcinoma, Non-Small-Cell Lung - Genetics
(55)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(53)
Respiratory System
(52)
Lung Neoplasms - Pathology
(50)
Animals
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

CT-Guided Percutaneous Cryoablation for Lung Metastasis of Colorectal Cancer: A Case Series

Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Suchergebnisse filtern